also on other fortune lists

company facts

f500 stats

Fortune 500

Kevin J. Miyazaki/Redux




AbbVie—a North Chicago, Ill.-based biopharmaceutical company—is laying the foundation for its future as the company looks to move beyond its flagship drug Humira. Global Humira sales dropped 5.6% to $4.4 billion in the first quarter of 2019. The drug took a steep 27.9% downturn in international markets during the same time period in part due to the entry of biosimilars in Europe. This contrasts with global Humira sales in FY2018, which increased 8.2% year-over-year to $19.9 billion. Still, AbbVie raised its earnings-per-share guidance for 2019 in April coming off the FDA approval of its drug Skyrizi. The plaque psoriasis drug has been reported to be set to launch later this year.

Looking for leads, investment insights, or competitive intelligence?


Richard A. Gonzalez

CEO Title

Chairman & Chief Executive Officer


Health Care



HQ Location

North Chicago, Ill.

Years on Fortune 500 List




Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$32,75316.1%
Profits ($M)$5,687.07.1%
Assets ($M)$59,352
Total Stockholder Equity ($M)$-8,446
Profit Ratios
Profit as % of Revenues17.4%
Profits as % of Assets9.6%
Profits as % of Stockholder Equity-
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)3.66
EPS % Change (from 2017)10.9%
EPS % Change (5 year annual rate)7.4%
EPS % Change (10 year annual rate)-
Total Return
Total Return to Investors (2018)-1.2%
Total Return to Investors (5 year, annualized)15.7%
Total Return to Investors (10 year, annualized)-
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about AbbVie

How the Best Workplaces in Health Care and Biopharma Are Winning the Talent War

Fortune research partner Great Place to Work has released its 2019 list of the best workplaces in health care and biopharma.

Read More →
Senator Calls Tying Drugmaker CEO Pay to High Drug Price 'Problematic'

A year's course of the blockbuster drug is $60,000, more than triple its initial 2012 price.

Read More →
Fortune's Blue Ribbon Companies 2018

These 56 companies are on at least four of Fortune's 2018 rankings.

Read More →
Drugmakers Celebrate the New Year by Raising Prices on Hundreds of Drugs an Average of 6.3%

The average price increase is nearly three times the current U.S. inflation rate.

Read More →
AbbVie Gets OK for Potential Blockbuster Endometriosis Treatment

AbbVie Inc. won U.S. approval for an oral medicine that treats pain caused by the gynecological disorder endometriosis.

Read More →